Visualization research on ENT1/NIS dual-function gene therapy to reverse drug resistance mediated by MUC1 in GEM-resistant pancreatic cancer.

[1]  J. Czernin,et al.  STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [18F]FLT PET imaging , 2021, Proceedings of the National Academy of Sciences.

[2]  R. Greil,et al.  Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. , 2021, European journal of cancer.

[3]  F. André,et al.  Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. , 2021, Cancer discovery.

[4]  R. Gargallo,et al.  Structural Effects of Incorporation of 2´-Deoxy-2´2´-difluorodeoxycytidine (Gemcitabine) in A- and B-form Duplexes. , 2021, Chemistry.

[5]  Z. Qian,et al.  Regulation of tumor microenvironment for pancreatic cancer therapy. , 2021, Biomaterials.

[6]  B. Rolando,et al.  Extracellular Matrix Composition Modulates the Responsiveness of Differentiated and Stem Pancreatic Cancer Cells to Lipophilic Derivate of Gemcitabine , 2020, International journal of molecular sciences.

[7]  Y. Nishiyama,et al.  Liver Abscess With High 18F-FDG Uptake and No 18F-Fluorothymidine Uptake. , 2020, Clinical nuclear medicine.

[8]  M. Diener,et al.  Top ten research priorities for pancreatic cancer therapy. , 2020, The Lancet. Oncology.

[9]  A. Maitra,et al.  Pancreatic cancer stroma: an update on therapeutic targeting strategies , 2020, Nature Reviews Gastroenterology & Hepatology.

[10]  Mo-Fang Liu,et al.  hENT1 Reverses Chemoresistance by Regulating Glycolysis in Pancreatic Cancer. , 2020, Cancer letters.

[11]  Mark B. Vestergaard,et al.  In vivo imaging of cell proliferation in meningioma using 3′-deoxy-3′-[18F]fluorothymidine PET/MRI , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  D. V. Von Hoff,et al.  Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.

[13]  B. V. Van Tine,et al.  Arginine Starvation and Docetaxel Induce c-Myc–Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors , 2019, Clinical Cancer Research.

[14]  Ho-Joon Lee,et al.  Macrophage Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer , 2018, bioRxiv.

[15]  Miao Zhang,et al.  Human sodium iodide transporter gene-mediated imaging and therapy of mouse glioma, comparison between 188Re and 131I. , 2018, Oncology letters.

[16]  Quan P. Ly,et al.  MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. , 2017, Cancer cell.

[17]  Z. Fan,et al.  Gemcitabine inhibits proliferation and induces apoptosis in human pancreatic cancer PANC-1 cells. , 2016, Journal of cancer research and therapeutics.

[18]  J. Roa,et al.  Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy‐naïve pT2 gallbladder adenocarcinoma patients , 2016, Histopathology.

[19]  P. Manoharan,et al.  18F-FLT PET imaging of cellular proliferation in pancreatic cancer. , 2016, Critical reviews in oncology/hematology.

[20]  Jiajia Hu,et al.  131I therapy mediated by sodium/iodide symporter combined with kringle 5 has a synergistic therapeutic effect on glioma. , 2016, Oncology reports.

[21]  Z. Werb,et al.  The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? , 2015, Cell stem cell.

[22]  G. Peters,et al.  Inhibition of thymidylate synthase by 2',2'-difluoro-2'-deoxycytidine (Gemcitabine) and its metabolite 2',2'-difluoro-2'-deoxyuridine. , 2015, The international journal of biochemistry & cell biology.

[23]  Jian Huang,et al.  The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment , 2014, Tumor Biology.

[24]  Carol E. Cass,et al.  Erlotinib, Gefitinib, and Vandetanib Inhibit Human Nucleoside Transporters and Protect Cancer Cells from Gemcitabine Cytotoxicity , 2013, Clinical Cancer Research.

[25]  M. Tempero,et al.  Therapeutic advances in pancreatic cancer. , 2013, Gastroenterology.

[26]  M. Sehested,et al.  [18F]FLT PET for Non-Invasive Assessment of Tumor Sensitivity to Chemotherapy: Studies with Experimental Chemotherapy TP202377 in Human Cancer Xenografts in Mice , 2012, PloS one.

[27]  B. Han,et al.  Feasibility of a novel positive feedback effect of 131I-promoted Bac-Egr1-hNIS expression in malignant glioma via baculovirus. , 2011, Nuclear medicine and biology.

[28]  Ru-fu Chen,et al.  In vivo Radioiodide Imaging and Treatment of Pancreatic Cancer Xenografts after MUC1 Promoter-Driven Expression of the Human Sodium-Iodide Symporter , 2007, Pancreatology.

[29]  B. Keil,et al.  Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivo , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  U. Haberkorn,et al.  99mTc-pertechnetate uptake in hepatoma cells due to tissue-specific human sodium iodide symporter gene expression. , 2006, Nuclear medicine and biology.

[31]  J. Shah,et al.  MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas. , 2005, Surgery.

[32]  M. Kumar,et al.  Amplification and functional characterization of MUC1 promoter and gene-virotherapy via a targeting adenoviral vector expressing hSSTR2 gene in MUC1-positive Panc-1 pancreatic cancer cells in vitro. , 2005, International journal of molecular medicine.

[33]  John R. Mackey,et al.  The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma , 2004, Clinical Cancer Research.

[34]  G. Peters,et al.  Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine) , 2002 .

[35]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Y. Namiki,et al.  Induction of the suicide HSV-TK gene by activation of the Egr-1 promoter with radioisotopes. , 1997, Human gene therapy.

[37]  V. Heinemann,et al.  Gemcitabine: metabolism, mechanisms of action, and self-potentiation. , 1995, Seminars in oncology.

[38]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[39]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[40]  John R. Mackey,et al.  Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. , 2014, Journal of the National Cancer Institute.

[41]  Michael R Lewis,et al.  A "new" reporter in the field of imaging reporter genes: correlating gene expression and function of the sodium/iodide symporter. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  Barry J. Allen,et al.  MUC1, MUC2, MUC4, MUC5AC and MUC6 Expression in the Progression of Prostate Cancer , 2005, Clinical & Experimental Metastasis.